• Health Care M&A Deals, September 18, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal... Read More »
  • MetLife Acquires Versant Health

    MetLife, Inc. (NYSE: MET) has entered the healthcare M&A market. Last week, the company announced the acquisition of Versant Health, the parent company of Davis Vision and Superior Vision, two major vision care and insurance brands with a combined 35 million members. Centerbridge Partners and an investor group including FFL Partners are... Read More »
  • CloudMD Expands Patient Engagement Portfolio

    CloudMD Software & Services Inc. (OTCMKTS: DOCRF) just keeps rolling out new deals and acquisitions. The company has been very active this year, with six acquisitions on the books so far across various sectors, according to search results in our Deal Search Online database. Last week, CloudMD acquired Toronto-based iMD Health Global Corp. for... Read More »
  • Trulieve Cannabis Boosts Its Market Reach

    Trulieve Cannabis Corp. (OTC: TCNNF), a vertically integrated “seed-to-sale” company and the first licensed medical cannabis company in the state of Florida, announced two new transactions last week. M&A activity in the medical marijuana market has been quiet throughout 2020 and 2019, after experiencing somewhat of a boom in 2018,... Read More »
  • A Busy Week for Home Health & Hospice Deals

    It was a busy week for home health & hospice (HH&H) transactions. Results from our Deal Search Online database show there were four announced last week alone, half of September’s total so far. Half of the deals were completed by private equity-backed companies, which highlights the continued interest in HH&H from PE firms. Jet... Read More »
Gilead Buys Kite Pharma to Diversify Portfolio

Gilead Buys Kite Pharma to Diversify Portfolio

Gilead Sciences, Inc. (NASDAQ: GILD) finally found a target worth pursuing. The pharmaceutical company, perhaps best known for its high-priced hepatitis-C drugs, Harvoni and Solvadi, placed its bets on Kite Pharma, Inc. (NASDAQ: KITE), hoping to cash in on the biotech’s promising technology for fighting cancer. Gilead announced the acquisition of Kite Pharma for $180.00 per share, valuing the company at approximately $11.9 billion. The price represents a 29% premium to Kite’s closing price on August 25, 2017. Kite Pharma is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer immunotherapy products. It is developing a pipeline of engineered... Read More »

Hanmi Pharmaceutical Deals with Sanofi, Janssen

Korean pharmaceutical company Hanmi Pharmaceutical Co., Ltd. popped up on the healthcare M&A radar last week with two collaboration announcements. First was an agreement with French drug maker Sanofi (NYSE: SNY) to grant the worldwide license to a yet-to-be developed portfolio of experimental, long-acting diabetes treatments. Sanofi paid an upfront fee of €400 million ($434,820,000) and is eligible for up to €3.5 billion in development, registration and sales milestone, as well as double digit royalties on net sales. The second deal, with Janssen Pharmacticals, Inc. (NYSE: JNJ), was for the rights to oxyntomodulin-based therapies, including Hanmi’s NM12525A. Janssen paid $105... Read More »

Janssen Scoops Up XO1

No, XO1 is not a drug candidate, it’s the name of an asset-centric virtual biopharmaceutical company, XO1 Limited, a UK-based portfolio company of Index Ventures. Janssen Pharmaceuticals (NYSE: JNJ) paid an undisclosed price for the virtual company, which was founded solely to develop the anti-thrombin antibody ichorcumab, which basically acts as an anticoagulant but doesn’t cause bleeding, like previous blood thinners. XO1 and Index Ventures licensed the technology from Cambridge University Hospitals, where it was developed. Read More »